ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2872

SLE Subjects Express High Levels of Intracellular Interferon-β That Acts in an Autocrine Fashion to Promote Survival of Transitional Stage B Cells

Jennie Hamilton1, Qi Wu2, PingAr Yang3, Bao Luo4, Shanrun Liu5, Jun Li6, Ignacio Sanz7, W. Winn Chatham8, Hui-Chen Hsu2 and John D. Mountz9, 1Medicine/Division of Clinical Immunology and Rhematology, University of Alabama at Birmingham, Birmingham, AL, 2Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 3Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 5Biochemistry & Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, 6Medicine, University of Alabama at Birmingham, Birmingham, AL, 7Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA, 8Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 9Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham, AL

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: B cells, interferons and tolerance, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  Upregulation of interferon-β (IFNβ) is an important step in promoting maturation and survival of B cells. Secretion and autocrine action of IFNβ requires assembly of the IFNβ enhanceosome, including IRF3, IRF7 and NF-ĸB. Interestingly, TLR7 stimulation has been found to induce IRF7 in transitional B cells from SLE patients. The purpose of this study is to determine if IFNβ is upregulated in transitional B cells of SLE patients and if autocrine activity of IFNβ promotes B cell survival.

Methods: Peripheral blood samples were obtained from consented SLE patients with active disease (SLEDAI > 6) during visits to a Lupus Clinic. FACS analysis was carried out using surface staining antibodies IgD, CD24, CD38, CD27 and CD19. Intracellular IFNβ was detected using and antihuman IFNβ (PBL, clone MMHB3). Autoreactive B cells were detected using 9G4. Transitional and mature 9G4+and 9G4B cell subsets were FACS sorted. qRT-PCR was carried using validated primers. Purified B cells were stimulated with TLR7 (CL264, 5 μg/ml) and a goat polyclonal antihuman IgM+IgG (5 μg/ml). IFNβ and IFNα/βR blocking was carried out using a polyclonal anti-IFNβ (500 IU/ml, PBL) and an IFNα/βR blocking Ab (anifrolumab, 5 μg/ml, Creative BioLabs), respectively.

Results:  There was a significant increase in intracellular IFNβ determined by both FACS analysis and by RT-PCR in IgD+CD24+CD38+CD27– transitional B cells of SLE patients compared to control subjects (p<0.01). IFNβ was upregulated in both the 9G4+ and 9G4– subpopulations of B cells. The expression of Ifnb in transitional cells further positively correlated with the expression of IFNα genes (Ifna1, Ifna2, and Ifna4) and IFN response genes (Mx1 and Ifit4) (p<0.05). TLR7 plus BCR stimulation upregulated IFNβ and resulted in a significant upregulation of CD69 and CD86 at 4 hrs by both transitional and mature B cells, and increase in survival at 60 hrs in B cells from SLE patients. Importantly, IFNβ neutralization inhibited these responses. The inhibition was equivalent to the blockade of IFNα/βR, indicating that although both IFNα and IFNβ were expressed, these early responses required the release and autocrine activity of intracellular IFNβ.

Conclusion:  The present results suggest that, in SLE, induction of type I IFN production by early transitional B cells is a 2-step process. IFNβ acts in an autocrine fashion to promote B cell survival and upregulation of IFNa. IFNa does not play an essential autocrine role but may act on other cells. B cell therapies directed at neutralizing IFNβ may be useful, especially in early-stage SLE prior to IFNβ enhanced development of IFNα producing B cells. Inhibition of IFNβ enhanceosome component(s) that are required for IFNβ production, may serve as a novel target for SLE. *(Supported by NIH R01-AI-071110, R01-AI-083705, P30-AR-048311, T32 AI007051, VA Merit Review grant 1I01BX000600, Lupus Research Institute, Lupus Foundation of America.)


Disclosure: J. Hamilton, None; Q. Wu, None; P. Yang, None; B. Luo, None; S. Liu, None; J. Li, None; I. Sanz, Takeda Pharmaceuticals, 2; W. W. Chatham, None; H. C. Hsu, None; J. D. Mountz, None.

To cite this abstract in AMA style:

Hamilton J, Wu Q, Yang P, Luo B, Liu S, Li J, Sanz I, Chatham WW, Hsu HC, Mountz JD. SLE Subjects Express High Levels of Intracellular Interferon-β That Acts in an Autocrine Fashion to Promote Survival of Transitional Stage B Cells [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/sle-subjects-express-high-levels-of-intracellular-interferon-%ce%b2-that-acts-in-an-autocrine-fashion-to-promote-survival-of-transitional-stage-b-cells/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sle-subjects-express-high-levels-of-intracellular-interferon-%ce%b2-that-acts-in-an-autocrine-fashion-to-promote-survival-of-transitional-stage-b-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology